Hepatic Impairment Study For Crizotinib In Advanced Cancer Patients
Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the potential effect of hepatic impairment on the
pharmacokinetics and safety of crizotinib in advanced cancer patients. Advanced cancer
patients with mild, moderate or severe liver dysfunction as well as patients with normal
liver function will be enrolled in this study.